HLscience Co., Ltd.
Financials
Valuation Metrics
HLscience Co., Ltd.'s Market Cap is ₩282B. At end of 2025 it was ₩436B. Ranked #2107 of 2,436 in KR market (top 86%), #1347 of 1,649 on KOSDAQ (top 82%), #44 of 57 in Household & Personal Products (top 77%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 28.20B KRW | KR#2,107/2,436 Sec#44/57 |
| Revenue | 13.76B KRW | KR#2,228/2,436 Sec#51/57 |
| Net Income | -11.36B KRW | KR—/2,436 Sec—/57 |
| Total Assets | 83.16B KRW | KR#1,884/2,436 Sec#40/57 |
| Net Assets | 80.89B KRW | KR#1,548/2,436 Sec#31/57 |
| Employees | 84 | KR#1,763/2,436 Sec#42/57 |
| Value | ||
| P/B | 0.35x | KR#437/2,436 Sec#7/57 |
| P/S | 2.05x | KR#1,832/2,436 Sec#45/57 |
| FCF Yield | -26.64% | KR—/2,436 Sec—/57 |
| Profitability | ||
| ROE | -14.04% | KR#1,973/2,436 Sec#46/57 |
| ROA | -13.66% | KR#2,153/2,436 Sec#52/57 |
| Op. Margin | -75.15% | KR#2,283/2,436 Sec#55/57 |
| Revenue Growth | -57.97% | KR#2,305/2,436 Sec#57/57 |
| Financial Health | ||
| Debt Ratio | 102.81% | KR#338/2,436 Sec#13/57 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/57 |
| FCF | -7.51B KRW | KR#1,619/2,436 Sec#45/57 |
| Cash | 1.68B KRW | KR#2,275/2,436 Sec#53/57 |
| Current Ratio | 15.16x | KR#51/2,436 Sec#2/57 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/57 |
| Performance | ||
| 1Y Return | -56.05% | KR#2,183/2,436 Sec#52/57 |
| 1M Return | -1.69% | KR#1,066/2,436 Sec#38/57 |
| From 52W High | -56.81% | KR#1,552/2,436 Sec#43/57 |
| 1Y MDD | -58.48% | KR#1,317/2,436 Sec#35/57 |
| Trading | ||
| Volume | 1,403 shares | KR#2,360/2,436 Sec#57/57 |
| Foreign Own. | 0.88% | KR—/2,436 Sec—/57 |
| Per Share | ||
| EPS | -2,095 KRW | KR—/2,436 Sec—/57 |
| BPS | 15,855 KRW | KR#621/2,436 Sec#14/57 |
Company Info
HL Science, originally Geongang Sarang, was founded in 2000 and listed on KOSDAQ in 2016. In 2022, it completed Korea's first Ministry of Food and Drug Safety-approved individually recognized raw material CDMO smart factory in Chungju, Chungcheongbuk-do. The company operates as a technology platform enterprise, focusing on research into new biomaterials and new technologies for bio healthcare, encompassing R&D, manufacturing, and sales. It has developed 12 individually recognized raw materials, securing 48 domestic and international patent registrations and 16 patent applications, establishing an integrated Value Chain system. Headquartered in Uiwang, Gyeonggi-do.